European Opportunities Trust: weak half-year, big strategic questions
European Opportunities Trust’s half-year numbers make for sober reading. Net asset value (NAV) total return came in at -0.2% for the six months to 30 November 2025, while the share price total return was 0.9%. Both trail the benchmark badly – the MSCI Europe Total Return Index in GBP returned 10.1%. In response, the Board has launched a Strategic Review to consider the future shape of the trust, including who manages it and what structure it should take.
Let’s unpack what happened, why it matters, and what to watch next.
Key half-year numbers investors need to see
| NAV total return (with dividends reinvested) | -0.2% |
| Share price total return (with dividends reinvested) | 0.9% |
| Benchmark (MSCI Europe TR in GBP) | 10.1% |
| NAV per share | 965.37p (from 968.89p, -0.4%) |
| Share price (period end) | 902.00p |
| Discount to NAV (period end) | 6.6% (vs 7.5% at 31 May 2025) |
| Net gearing (borrowing as a % of net assets) | 13.7% (vs 7.2% at 31 May 2025) |
| Dividend paid | 2.0p (28 October 2025) |
| Net assets | £450.4 million |
| Shares in issue | 46,659,442 |
Long-term, the picture is mixed. Since launch in 2000, annualised NAV total return is 10.2% (share price 9.7%), ahead of the benchmark’s 6.5%. But more recent periods show clear underperformance versus the index:
- 3 years: NAV +15.2% vs benchmark +46.2%
- 5 years: NAV +25.4% vs benchmark +71.7%
- 10 years: NAV +80.0% vs benchmark +157.9%
Strategic Review: what’s on the table and why it matters
The Board has begun a Strategic Review of the trust’s future, including “ongoing investment management arrangements.” This follows persistent underperformance and the likely failure to meet a performance condition tied to a performance-related tender offer due later this year. There’s also a continuation vote at the 2026 AGM.
Options under active consideration include:
- A combination with another closed-ended fund via a section 110 scheme of reconstruction
- A cash exit for shareholders at close to NAV
- A roll-over into a proposed open-ended investment company (OEIC) from River Global with a similar mandate
In plain English: anything from a merger to a wind-down-style exit to a move into an OEIC is possible. There is no certainty of change, but the menu is wide. For discount-watchers, corporate action often acts as a catalyst – good or bad – for narrowing the gap to NAV.
Performance drivers: where it went right and wrong
Stock winners and themes that helped
- Genus (+32.8% total return; 7.3% portfolio weight; 2.4% contribution): FDA approval for gene editing technology and firm trading supported the move.
- Prysmian (+58.8%; 5.2% weight; 2.3% contribution): a pure play on grid upgrades and AI-driven electrification.
- Camurus (+25.3%; 5.7% weight; 1.0% contribution): drug delivery tie-up with a leading US pharma boosted confidence.
- Ryanair (+25.7%; 3.7% weight; 0.9% contribution): capacity tightness and pricing power underpin profit growth.
- Grifols (+17.0%; 4.3% weight; 0.6% contribution): recovery from Covid-era issues continued.
Pain points that dragged returns
- Dassault Systèmes (-23.9% total return; 6.6% weight; -1.8% contribution): slower growth and automotive end-market caution.
- RELX (-23.8%; 6.0% weight; -1.6% contribution): sentiment swing on perceived AI threats, despite higher reported growth rates.
- Novo Nordisk (-27.0%; 6.4% weight; -1.5% contribution): management changes, US market share losses and policy headwinds.
- Edenred (-26.9%; 3.6% weight; -1.1% contribution): regulatory changes rattled investors; manager argues the model remains intact.
- Deutsche Börse (-15.1%; 5.2% weight; -0.8% contribution): weakness despite resilient franchise characteristics.
The portfolio remains thematically tilted to AI, electrification and defence. Defence names – Thales, Exosens and BAE Systems – total 5.1% of the portfolio. Health Care is the largest sector at 33.3%; Industrials is 29.8%; IT is 11.6%; Financials 15.9%. The trust holds 26 positions, with notable weights in Genus (8.4%), Camurus (6.7%), Dassault Systèmes (6.2%), Novo Nordisk (6.1%) and Prysmian (6.0%).
Fees, manager changes and governance tweaks
- Manager ownership: Devon Equity Management was acquired by River Global PLC on 6 October 2025. The Board’s initial stance is broadly positive, citing added resources and distribution.
- Fees cut: from 1 October 2025, a tiered fee of 0.65% up to £400 million, 0.60% between £400 million and £600 million, and 0.55% above £600 million. Previously 0.80%/0.70%/0.60% at higher asset tiers. Lower fees help – but performance is still king.
- Company secretary: Juniper Partners appointed from 1 January 2026.
Discount and buyback stance
The discount sat at 6.6% at period end, wider than the AIC Europe sector weighted-average 3.0% on 30 November 2025. The Board’s policy is to keep the discount in single digits in normal markets using buybacks. No buybacks were needed in the period as the discount stayed within single digits. A chunky 25% tender at close to NAV in June 2025 was fully subscribed, taking net assets to £463 million at 30 June 2025. As at 31 January 2026, the discount was 6.7%.
My take: the Strategic Review is likely to keep the discount in focus. A credible solution – merger, exit, or roll-over – could tighten it. But uncertainty can also weigh if the process drifts.
Gearing, liquidity and capital moves
Net gearing rose to 13.7% from 7.2%, supported by a £70 million secured multi-currency revolving credit facility. The trust raised roughly £148 million from sales to fund the June tender, selling £277.9 million and reinvesting £174.8 million. Underlying annualised turnover (excluding tender flows) was 25.7%.
In my view, higher gearing amplifies outcomes from here – helpful if the stock-picking rebounds, unhelpful if the style headwinds persist.
Financials at a glance
- Total net return after tax: -£2.3 million (revenue +£0.6 million, capital -£2.9 million)
- Management fee for the period: £1.636 million (down from £2.458 million in the prior interim)
- Finance costs: £1.481 million
- Cash: £4.1 million (from £25.4 million at 31 May 2025)
- Investments at fair value: £510.2 million
What I’m watching next
- Strategic Review milestones: clarity on preferred route – section 110 combination, cash exit, or OEIC roll-over – and expected timetable.
- Continuation vote at the 2026 AGM: the ultimate barometer of shareholder confidence.
- Performance of key detractors: evidence that Novo Nordisk stabilises, Edenred’s regulatory impact normalises, and sentiment around RELX’s AI positioning improves.
- Discount behaviour: any narrowing on corporate news; any buyback activity if the discount gaps out.
- Gearing: whether 13.7% is maintained, raised or trimmed as markets move.
Bottom line: a credible reset is needed
This is a tough tape for European Opportunities Trust. Short-term returns lagged materially, and medium-term record trails the benchmark. The Board has, to its credit, put everything on the table – fee cuts, big tenders, and now a full Strategic Review. That’s the right instinct when performance isn’t delivering.
For investors, the set-up is twofold. On the one hand, you have a 6.6% discount, lower fees, and potential corporate catalysts. On the other, you’ve got style headwinds, elevated gearing, and big calls to land on the review. If the team can turn stock-picking momentum – with themes like grid electrification and defence already contributing – there’s upside. If not, the review provides an exit path at or around NAV. Either way, this is one to watch closely over the coming months.
